Comprehensive Analysis of U.S. Patent 6,332,985: Scope, Claims, and Patent Landscape

Summary

Patent 6,332,985, issued to Glaxo Group Ltd. on December 11, 2001, protects a pharmaceutical compound primarily associated with the treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). This analysis dissects the scope and claims of the patent, annotates key elements, compares it to equivalent patents or applications, and maps the broader patent landscape. Its insights are crucial for pharmaceutical stakeholders, legal professionals, and competitors assessing freedom-to-operate, licensing, or litigation risks.

What Is the Scope of Patent 6,332,985?

Patent Overview

Title: (Not specified in the prompt; typically relates to a compound for respiratory use)
Assignee: Glaxo Group Ltd. (now part of GSK)
Filing Date: December 4, 1997
Issue Date: December 11, 2001
International Classification (IPC): A61K 31/015 (heterocyclic compounds), A61K 31/198 (pyridines, cyclic amines), and related classifications.

The Patent’s Focus

Patent 6,332,985 claims a novel class of substituted pyridine derivatives characterized by specific chemical structures and their use as bronchodilators and anti-inflammatory agents. The emphasis is on compounds with a particular substituent pattern that enhances potency and pharmacokinetic properties.

Core Description

The patent's core encompasses:

A chemical formula (represented generally as a heteroarylalkyl derivative) with particular substituents at specific positions.
Variations thereof, with specified heteroatoms and substituents (e.g., methyl, ethyl, fluoro).
Methods of making such compounds.
Use of these compounds in respiratory disease therapy, particularly via inhalation.

Patent Claims

The claims are the legal definition of patent protection. Patent 6,332,985’s claims can be distilled into three main categories:

Claim Type	Scope Summary	Number of Claims
Compound Claims	A chemical compound or a class of derivatives with specific structural features	30+ (varies depending on embodiments)
Use Claims	Therapeutic use of the compounds for respiratory conditions like asthma	10+
Method Claims	Methods of synthesis and formulation for the compounds	5+

Analysis of Key Claims

Representative Compound Claims

These typically cover compounds with the following structure (general formula I):

Core structure: A heteroaryl ring (e.g., pyridine) attached to an alkyl chain, substituted with functional groups like fluoro, methoxy, etc.
Substitutions: Specific positions on the heteroaryl ring or alkyl linker, leading to variations within the scope.

Example Claim (paraphrased):
"A compound having the general formula I, wherein R1, R2, and R3 are selected from a group consisting of hydrogen, alkyl, fluoro, or methoxy groups, with specified positional relationships."

Use and Method Claims

The patent explicitly claims the use of these compounds as bronchodilators and anti-inflammatory agents.
Also claims methods of preparing the compounds, such as steps involving halogenation, alkylation, or heterocycle formation.

Scope & Limitations

The scope focuses narrowly on compounds with the described chemical motif; broader claims are mitigated by specific structural limitations.
The claims do not encompass all heteroaryl derivatives but target a specific subclass relevant to the therapeutic focus.

Patent Landscape and Prior Art

Patent Family and Related Patents

The patent belongs to a family of patents seeking protection for pyridine-based compounds for respiratory treatments.
Similar patents pursued by GSK include WO 98/18455, covering pyridine derivatives with anti-asthmatic activity.

Key Prior Art

EP 679,429 (A pharmaceutical composition incorporating pyridine derivatives)
US 5,849,908 (Compounds for respiratory ailments with a similar heteroaryl scaffold)
WO 96/35655 (Pyridine derivatives for PDE4 inhibition)

Licensing and Litigation

No public major litigation or licensing disputes are explicitly documented concerning this patent as of 2023, but it forms part of GSK's broader respiratory patent portfolio, often used defensively or in licensing strategies.

Patent Term and Patent Life

Filing in 1997, with a 20-year term, the patent expired around December 2017, based on patent term calculations, assuming no terminal disclaimers or extensions.
Since expiry, the compound or similar derivatives are likely in the public domain.

Comparison to Contemporary Patents

Aspect	Patent 6,332,985	Contemporaneous Patent (e.g., WO 98/18455)	Differences
Scope	Specific heteroaryl derivatives	Broader heterocyclic compounds	Narrower, structurally focused
Claims	Compound + use	Compound + formulation + use	More comprehensive coverage in latter
Status	Expired 2017	Typically still active (if filed; varies)	Expiry opens field for generics

Implications for Stakeholders

For Patent Holders and R&D

The patent’s expiration indicates that the specific compounds are now open for generic development, provided no other active patents constrain the space.
Newer patents may focus on improved formulations, delivery mechanisms, or second-generation compounds.

For Competitors and Generic Manufacturers

Freedom to operate post-2017 for the original compounds and their obvious derivatives.
However, vigilance is necessary for secondary patents covering formulations, delivery devices, or polymorphs.

For Licensees

Existing license agreements or cross-licensing deals might have covered the patent during its active life, conferring valuable rights or restrictions.

Key Takeaways

Patent 6,332,985 protects a specific class of pyridine derivatives for respiratory treatment, focusing sharply on compounds with defined structural variations.
The claims cover both compound structures and their therapeutic applications, emphasizing bronchodilatory and anti-inflammatory activity.
The patent landscape reveals overlapping protection with prior art, but the patent's expiration in 2017 has shifted the competitive landscape favorably for generic manufacturers.
Contemporary research continues to refine and develop derivatives within or beyond the scope of this patent, emphasizing the ongoing innovation in respiratory pharmacology.
Legal and commercial decisions should consider the expiry, existing patent territory, and potential secondary patents.

FAQs

1. What is the main chemical class covered by U.S. Patent 6,332,985?

It primarily covers substituted pyridine derivatives, characterized by specific heteroaryl substitutions and functional groups designed for respiratory therapeutic use.

2. When did the patent expire, and what does that mean for drug development?

The patent expired around December 2017, opening the pathway for generic manufacturers to produce and market similar compounds without infringing the patent.

3. Are there any active patents similar to 6,332,985?

Yes, several related patents, such as WO 98/18455, cover similar compounds and formulations, especially for delivering improved efficacy or novel delivery systems.

4. What therapeutic uses are claimed in this patent?

Primarily treatment of respiratory disorders such as asthma and COPD via bronchodilation and anti-inflammatory mechanisms.

5. How does this patent landscape affect current R&D strategies?

While original patent rights are expired, continuing innovation in derivative compounds, delivery formulations, or combination therapies represents ongoing R&D opportunities.

References

United States Patent 6,332,985. Glaxo Group Ltd. – Issued Dec 11, 2001.
EP 679,429. (European Patent) – Similar class of pyridine derivatives.
US 5,849,908. (Prior art for heteroaryl compounds).
WO 98/18455. (Pyridine derivatives with respiratory activity).
Patent Term Calculator. (Govt. databases for patent expiry analysis).

Details for Patent: 6,332,985

Summary for Patent: 6,332,985